Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasms 2Uterine Cervical Neoplasms 1Sarcoma, Ewing 1Neuroectodermal Tumors, Primitive 1Lymphoma 1Endometrial Neoplasms 1

Interventions

Temozolomide 11Cyclophosphamide 11Radiotherapy 7Magnetic Resonance Spectroscopy 6Filgrastim 6Cisplatin 6Vincristine 5Etoposide 5Carboplatin 5antineoplaston AS 2-1 4antineoplaston A10 4sargramostim 3Thiotepa 3Melphalan 3Carmustine 3Automobiles 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3gallium Ga 68 dotatate 2fludarabine 2dactolisib 2aldesleukin 2Thalidomide 2TH 302 2Paclitaxel 2Irinotecan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Gadolinium DTPA 2Everolimus 2Donepezil 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neuroectodermal Tumors, Primitive × PM 00104 × Clear all
NCT01222767 2021-10-29

Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy

PharmaMar

Phase 2 Completed
17 enrolled 20 charts
Sarcoma

Sarcoma, Ewing, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon ⚡